1,307 United Therapeutics Corporation $UTHR Shares Sold by Teachers Retirement System of The State of Kentucky

Teachers Retirement System of The State of Kentucky cut its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR – Free Report) by 4.7% during the third quarter, Holdings Channel reports. The fund owned 26,725 shares of the biotechnology company’s stock after selling 1,307 shares during the period. Teachers Retirement System of The State of Kentucky’s holdings in United Therapeutics were worth $14,483,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of UTHR. HighTower Advisors LLC raised its position in United Therapeutics by 19.1% in the 3rd quarter. HighTower Advisors LLC now owns 4,775 shares of the biotechnology company’s stock valued at $2,587,000 after purchasing an additional 767 shares during the last quarter. Harbour Investments Inc. boosted its stake in United Therapeutics by 47.3% in the third quarter. Harbour Investments Inc. now owns 134 shares of the biotechnology company’s stock worth $73,000 after purchasing an additional 43 shares in the last quarter. Danske Bank A S grew its holdings in shares of United Therapeutics by 2.0% during the third quarter. Danske Bank A S now owns 18,709 shares of the biotechnology company’s stock worth $10,138,000 after purchasing an additional 360 shares during the last quarter. Aberdeen Group plc grew its holdings in shares of United Therapeutics by 9,760.9% during the third quarter. Aberdeen Group plc now owns 50,981 shares of the biotechnology company’s stock worth $27,626,000 after purchasing an additional 50,464 shares during the last quarter. Finally, Allworth Financial LP grew its holdings in shares of United Therapeutics by 3.5% during the third quarter. Allworth Financial LP now owns 1,208 shares of the biotechnology company’s stock worth $655,000 after purchasing an additional 41 shares during the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on UTHR. HC Wainwright initiated coverage on United Therapeutics in a research note on Monday, November 9th. They issued a “buy” rating and a $660.00 target price for the company. JPMorgan Chase & Co. reduced their price target on shares of United Therapeutics from $710.00 to $695.00 and set an “overweight” rating on the stock in a research report on Wednesday, October 28th. Raymond James Financial set a $720.00 price objective on shares of United Therapeutics in a report on Wednesday, November 4th. TD Cowen increased their price objective on shares of United Therapeutics from $675.00 to $700.00 and gave the stock a “buy” rating in a report on Thursday, November 5th. Finally, Morgan Stanley raised their price objective on shares of United Therapeutics from $515.00 to $566.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 7th. Twelve analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $676.40.

Check Out Our Latest Stock Analysis on United Therapeutics

Insider Activity at United Therapeutics

In other United Therapeutics news, Director Christopher Patusky sold 1,210 shares of United Therapeutics stock in a transaction dated Monday, November 9th. The stock was sold at an average price of $580.00, for a total transaction of $701,800.00. Following the transaction, the director directly owned 2,140 shares in the company, valued at approximately $1,241,200. The trade was a 36.12% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Martine Rothblatt sold 9,500 shares of the business’s stock in a transaction that occurred on Monday, November 16th. The shares were sold at an average price of $587.74, for a total value of $5,583,530.00. Following the completion of the transaction, the chief executive officer owned 324,443 shares of the company’s stock, valued at $190,688,128.82. This represents a 2.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 412,238 shares of company stock worth $222,367,801 in the last quarter. Corporate insiders own 8.60% of the company’s stock.

United Therapeutics Trading Down 0.6%

NASDAQ:UTHR opened at $584.10 on Wednesday. United Therapeutics Corporation has a 1-year low of $455.63 and a 1-year high of $614.23. The firm has a market capitalization of $24.88 billion, a price-to-earnings ratio of 22.04, a PEG ratio of 3.91 and a beta of 0.49. The business’s 50-day moving average price is $546.33 and its two-hundred day moving average price is $537.56.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last issued its earnings results on Wednesday, November 4th. The biotechnology company reported $5.71 EPS for the quarter, missing the consensus estimate of $6.01 by ($0.30). The firm had revenue of $832.50 million during the quarter, compared to the consensus estimate of $781.14 million. United Therapeutics had a net margin of 38.61% and a return on equity of 19.18%. The firm’s revenue for the quarter was up 4.1% on a year-over-year basis. During the same period in the previous year, the company posted $7.16 EPS. Sell-side analysts predict that United Therapeutics Corporation will post 25.08 earnings per share for the current year.

United Therapeutics announced that its board has initiated a stock buyback plan on Thursday, October 22nd that permits the company to buy back $2 billion in outstanding shares. This repurchase authorization permits the biotechnology company to repurchase up to 8.3% of its stock through open market purchases. Share repurchase plans are usually an indication that the company’s management believes its shares are undervalued.

United Therapeutics Company Profile

(Free Report)

United Therapeutics is a biotechnology company that develops and commercializes treatments for serious diseases, with a primary focus on pulmonary arterial hypertension (PAH). Its therapies include treprostinil products delivered by injection, inhalation, or oral tablet, marketed under brands including Remodulin, Tyvaso, and Orenitram. The company also markets Unituxin, a treatment for high-risk neuroblastoma. Founded in 1996 by Martine Rothblatt, United Therapeutics is also pursuing technologies intended to address the shortage of transplantable organs.

See Also

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR – Free Report).

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.